Immuno-Oncology | Specialty

Dr. Agarwala on the Role of Cytokines in the Immunotherapy Landscape

April 2nd 2015

Sanjiv S. Agarwala, MD, Chief of Medical Oncology, Hematology, St. Luke's Cancer Center and Temple University, discusses the differences between cytokines and other types of immunotherapies.

Dr. Garcia on Challenges With Immunotherapy in Prostate Cancer

April 1st 2015

Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.

Dr. Joseph on Necessary Improvements on Immunotherapy in Melanoma

March 31st 2015

Richard W. Joseph, MD, Department of Hematology/Oncology, Mayo Clinic, discusses some improvements needed in the field of immunotherapy as a treatment for melanoma.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30th 2015

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.

Dr. Jedd Wolchok on Immunotherapy Toxicities

March 30th 2015

Jedd Wolchok, MD, PhD, chief, of Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with immunotherapy.

Novel Therapies Needed for Muscle-Invasive Bladder Cancer

March 27th 2015

Anti-PD-L1 Therapy in Muscle-Invasive Bladder Cancer

March 27th 2015

Potential Targets in Muscle-Invasive Bladder Cancer

March 27th 2015

Treating Relapsed Muscle-Invasive Bladder Cancer

March 27th 2015

Cisplatin-Based Therapy in Muscle-Invasive Bladder Cancer

March 27th 2015

Multidisciplinary Approach in Muscle-Invasive Bladder Cancer

March 27th 2015

Neoadjuvant and Adjuvant Therapy in Bladder Cancer

March 27th 2015

Managing Renal Pelvis Transitional Cell Carcinoma

March 27th 2015

Lymph Node Dissection in Bladder Cancer

March 27th 2015

Introduction: Neoadjuvant Chemotherapy in Bladder Cancer

March 27th 2015

Dr. Alan Miller on Immunotherapy for Cancer Treatment

March 26th 2015

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System, discusses immunotherapy for cancer treatment.

Genetic Testing in RCC

March 26th 2015

Immune Checkpoint Inhibition in RCC

March 26th 2015

Second-Line Cabozantinib in mRCC

March 26th 2015

Second-Line Treatments in RCC

March 26th 2015